Didanosine

CHEMBL1460 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
236.2 g/mol
LogP
-1.2
Phase
4

A nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV infection by blocking the viral enzyme reverse transcriptase needed to make copies of the virus. It must be taken on an empty stomach for adequate absorption. Serious risks include pancreatitis and peripheral neuropathy, and it should not be combined with certain other antivirals.

Masse moléculaire

236,2300 g/mol

LogP

-1,20

TPSA

88,70 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1

InChI

InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1

Molecular Formula

C10H12N4O3

HBD / HBA

2 / 5

Liaisons Rotatives

2

Atomes Lourds

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV infection by blocking the viral enzyme reverse transcriptase needed to make copies of the virus. It must be taken on an empty stomach for adequate absorption. Serious risks include pancreatitis and peripheral neuropathy, and it should not be combined with certain other antivirals.

Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.

Yes, Didanosine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1460. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 135398739. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.